A drug discovery platform
for genetic diseases
A drug
discovery
engine for
genetic
diseases
for genetic diseases
discovery
engine for
genetic
diseases
Rapidly produce novel drug & target combinations
that are effective for multiple indication
that are effective for multiple indication
From personalized medicine for individuals to precision medicine for populations
QRGenetics develop a powerful AI-supported drug discovery engine
that utilizes exclusive spatial analytics and proprietary omics datasets,
to rapidly produce novel drug and target combinations
that are effective for multiple indication
From personalized medicine for individuals to precision medicine for populations QRGenetics develop a powerful AI-supported drug discovery engine
that utilizes exclusive spatial analytics and proprietary omics datasets,
to rapidly produce novel drug and target combinations
that are effective for multiple indication
Our Unique Discovery Process
Consolidate
Medical
data
data
Disease
data
data
Proprietary
database
database
Proprietary
Algorithms
Algorithms
Disease
Modeling
Modeling
Protein
Modeling
Modeling
Target
Identification
Identification
Drug
Discovery
Discovery
Validate
Rapid clinical validation through preclinical tests, & in-human trials
Expand
Proprietary
Algorithms
Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders
Power
Create a vast library of validated drug + target combinations, ready for clinical trials
Our Discovery Edge
Expanding Indications
extend the impact of our treatments, benefiting a broader range of patients
extend the impact of our treatments, benefiting a broader range of patients
Rapid Target & Drug Identification
Accelerating from years
to months
Accelerating from years
to months
New Market Demand
for shelf products, developed drugs and patented drugs
for shelf products, developed drugs and patented drugs
From Rare Disease to Heart Failure
Rare Indication
2 years old
Was diagnosed with a rare genetic disease caused by a point mutation that impacted blood supply to multiple organs and affect growth and development
Matching treatment
FDA-approved drug was matched and tested in a pre-clinical trial
Based on the results, an IND was submitted and a multicentre clinical trial was initiated
Drug Indication
Expansion
Same drug was also found beneficial for
1,000,000
patients that suffers from heart failure
Pipeline
Drug
name
name
Indication
type
type
Indication
name
name
Pre-clinical trial
Results
Clinical partner research
Clinical trial
QR-100
Rare
Common
Neurodevelopmental disorder (NDPLH)
Autism Spectrum Disorder (ASD)
QR-755
Rare
Common
Common
Celiac Disease
Rheumatoid Arthritis (RA)
Inflammatory Bowel Disease (IBD)
QR-172
Rare
Common
Common
Common
Common
Common
Common
Common
Smooth Muscle Disease
Heart failure
Abdominal and aortic Aneurysm
Visceral myopathy
Deafness
Dystonia
Myopathy
Basal cell carcinoma
Management Team
Dr. Shane Wald Altman. Ph.D.
Co-Founder & CEO
Prof. Miguel Weil, Ph.D.
Co-Founder & Scientific advisor
Dan Lavi
Co-Founder, Entrepreneur
& Business Management
& Business Management
Dr. Noa Bielopolski, Ph.D.
Director of Science
Advisory Board
Ido Gonen
Board Member and
Business development
consultant
Business development
consultant
Dr. Dan Goldstaub
Board member
and Pharma consultant
and Pharma consultant
Prof. Arnold Levine
Board Member and
Cancer research specialist
Cancer research specialist
Prof. Hagit Baris Feldman
Genetic advisor
